Brentuximab vedotin Effectively Treats Patients With Relapsed or Refractory Hodgkin Lymphoma Post Autologous Stem Cell Transplantation

British Journal of Haematology
14 Feb, 2020 ,

Kaloyannidis P et al compared salvage chemotherapy with brentuximab vedotin in terms of efficacy to treat relapsed refractory classical Hodgkin lymphoma patients post autologous stem cell transplantation. The findings revealed improvements in both clinical responses, as well as overall survival, was achieved with the use of BV as first salvage therapy in cHL patients relapsing or progressing after ASCT.